DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$89.75
-1.73 (-1.89%)
▼
5d:
+5.9%
30d:
+15.09%
90d:
+55.22%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 7, 2026 at $84.75 · last confirmed Aug 12, 2026
Strength: 5.9/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DXCM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DXCM shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$125.64
Based on 10.7% avg growth
INTRINSIC VALUE TODAY
$78.01
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $89.75, which is considered extended relative to its 30-day fair value range of $72.16 to $85.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 28.7) compared to its historical average (24.3). At these levels, the market is pricing in 5.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DXCM is in a strong uptrend. The price is approaching resistance at $91.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DXCM scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DXCM is in a strong uptrend. The price is approaching resistance at $91.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DXCM scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$72.16 -
$85.50
Company Quality Score
28/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.9%
Protect Your Profits
Holding DXCM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($93.44)
- NEUTRAL: Trading at premium valuation - market expects 5.7% growth which is achievable
- WARNING: Composite score 28/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$72.16 -
$85.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$82.09
Resistance Level
$91.96
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.72
Wall Street Target
$93.44
(+4.1%)
Revenue Growth (YoY)
13.1%
Earnings Growth (YoY)
43.6%
Profit Margin
20.1%
Valuation Premium vs History
+5.7% premium
PE vs Historical
28.7 vs 24.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.7%
(market-implied from PE analysis)
1-Year Target
$94.87
(+6%)
2-Year Target
$100.27
(+12%)
3-Year Target
$105.99
(+18%)
3-Yr Target (if PE normalizes)
(PE: 29→24)
PE COMPRESSION
$89.66
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.7, Growth: 17.4%)
$145.08
(+62%)
Base:
(SPY PE: 20.2, Growth: 17.4%)
$102.18
(+14%)
Bear:
(PE: 17.2, Growth: 17.4%)
$86.85
(-3%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 35.87 | Current EPS (TTM): $2.55
Bull Case
$123.30
(+37%)
Analyst growth 22.5%, PE expands to 39.5
Base Case
$112.09
(+25%)
Market implied 22.5%, PE stable at 35.9
Bear Case
$62.21
(-31%)
Severe decline -20.0%, PE contracts to 30.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 16, 2026 3:00 AM ET
Data refreshes hourly during market hours. Next update: 4:00 AM
Data refreshes hourly during market hours. Next update: 4:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 33 SELL |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$382 | 48 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 55 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 41 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 29 SELL |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
